These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2038 related items for PubMed ID: 29691490

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Role of CGRP in Migraine.
    Edvinsson L.
    Handb Exp Pharmacol; 2019; 255():121-130. PubMed ID: 30725283
    [Abstract] [Full Text] [Related]

  • 3. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [Abstract] [Full Text] [Related]

  • 4. CGRP and migraine: from bench to bedside.
    Edvinsson L.
    Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR.
    Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Migraine therapeutics differentially modulate the CGRP pathway.
    Bhakta M, Vuong T, Taura T, Wilson DS, Stratton JR, Mackenzie KD.
    Cephalalgia; 2021 Apr; 41(5):499-514. PubMed ID: 33626922
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Calcitonin Gene-Related Peptide-Targeted Therapies for Migraine and Cluster Headache: A Review.
    Schuster NM, Rapoport AM.
    Clin Neuropharmacol; 2017 Apr; 40(4):169-174. PubMed ID: 28644160
    [Abstract] [Full Text] [Related]

  • 11. A new era for migraine: The role of calcitonin gene-related peptide in the trigeminovascular system.
    Chen ST, Wu JW.
    Prog Brain Res; 2020 Apr; 255():123-142. PubMed ID: 33008504
    [Abstract] [Full Text] [Related]

  • 12. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T, Villalón CM, MaassenVanDenBrink A.
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [Abstract] [Full Text] [Related]

  • 13. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ.
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [Abstract] [Full Text] [Related]

  • 14. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment.
    Edvinsson L, Warfvinge K.
    Cephalalgia; 2019 Mar; 39(3):366-373. PubMed ID: 29020807
    [Abstract] [Full Text] [Related]

  • 15. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P.
    J Headache Pain; 2019 Jan 16; 20(1):6. PubMed ID: 30651064
    [Abstract] [Full Text] [Related]

  • 16. The CGRP Pathway in Migraine as a Viable Target for Therapies.
    Edvinsson L.
    Headache; 2018 May 16; 58 Suppl 1():33-47. PubMed ID: 29697153
    [Abstract] [Full Text] [Related]

  • 17. CGRP monoclonal antibodies and CGRP receptor antagonists (Gepants) in migraine prevention.
    Caronna E, Alpuente A, Torres-Ferrus M, Pozo-Rosich P.
    Handb Clin Neurol; 2024 May 16; 199():107-124. PubMed ID: 38307640
    [Abstract] [Full Text] [Related]

  • 18. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants.
    Chiang CC, Schwedt TJ.
    Prog Brain Res; 2020 May 16; 255():143-170. PubMed ID: 33008505
    [Abstract] [Full Text] [Related]

  • 19. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A, Pozo-Rosich P.
    Lancet; 2019 Nov 09; 394(10210):1765-1774. PubMed ID: 31668411
    [Abstract] [Full Text] [Related]

  • 20. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G, Navarra P.
    Peptides; 2019 Jun 09; 116():16-21. PubMed ID: 31018157
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 102.